Followers | 42 |
Posts | 5751 |
Boards Moderated | 0 |
Alias Born | 04/12/2021 |
Tuesday, October 11, 2022 7:10:00 AM
This prospectus also covers any additional shares of common stock that may become issuable upon any anti-dilution adjustment pursuant to the terms of the Warrants issued to the Selling Stockholders by reason of stock splits, stock dividends, and other events described therein.
The Selling Stockholders, or their respective transferees, pledgees, donees or other successors-in-interest, may sell the Placement Shares or the Warrant Shares through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices. The Selling Stockholders may sell any, all or none of the securities offered by this prospectus, and we do not know when or in what amount the Selling Stockholders may sell their Placement Shares or Warrant Shares hereunder following the effective date of this registration statement. We provide more information about how a Selling Stockholder may sell its Placement Shares or Warrant Shares in the section titled “Plan of Distribution” on page 165.
We are registering the Placement Shares and Warrant Shares on behalf of the Selling Stockholders, to be offered and sold by them from time to time. We will not receive any proceeds from the sale of our common stock by the Selling Stockholders in the offering described in this prospectus. We cannot predict when and in what amounts or if the Warrants will be exercised. We have agreed to bear all of the expenses incurred in connection with the registration of the Placement Shares and the Warrant Shares. The Selling Stockholders will pay or assume discounts, commissions, fees of underwriters, selling brokers or dealer managers and similar expenses, if any, incurred for the sale of the Placement Shares and the Warrant Shares.
We are an “emerging growth company” and a “smaller reporting company” as such terms are defined under federal securities laws, and, as such have elected to take advantage of certain reduced public company reporting requirements for this prospectus and may elect to do so in future filings.
This prospectus describes the general manner in which the Placement Shares and the Warrant Shares may be offered and sold.
If necessary, the specific manner in which the Placement Shares and the Warrant Shares may be offered and sold will be described in a supplement to this prospectus.
Our shares of common stock have experienced extreme volatility in market prices and trading volume since listing. From February 18, 2022 (the date our shares were initially listed on Nasdaq) to the date hereof, the market price of our common stock has fluctuated from an intra-day low on Nasdaq of $1.80 on July 15, 2022 to an intra-day high of $90.90 per share on February 22, 2022. By comparison, our initial public offering, which closed on February 23, 2022, was conducted at $9.00 per share. During this time, we have made six announcements regarding certain research developments and partnerships for our vaccine candidates. Notwithstanding the foregoing, since our initial public offering on February 18, 2022, there were no material recent publicly disclosed changes in the financial condition or results of operations of the Company, such as our earnings or revenue, that are consistent with or related to the changes in our stock price. The trading price of our common stock has been, and may continue to be, subject to wide price fluctuations in response to various factors, many of which are beyond our control, including those described under the heading “Risk Factors” beginning on page 14 of this prospectus.
Investing in our common stock involves a high degree of risk. Please read “Risk Factors” beginning on page 14 of this prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
The date of this prospectus is September 19, 2022
”
my posts are always theory and not financial advice
Recent ONCO News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2024 08:45:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2024 03:50:30 PM
- Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders • GlobeNewswire Inc. • 09/20/2024 03:45:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/03/2024 07:11:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/03/2024 07:10:25 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/29/2024 11:38:07 AM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 08:16:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 08:05:28 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/01/2024 08:05:12 PM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 07/22/2024 09:00:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 10:04:39 AM
- Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds • GlobeNewswire Inc. • 07/15/2024 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2024 12:31:06 PM
- Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds • GlobeNewswire Inc. • 07/11/2024 12:17:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 06/14/2024 09:09:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 08:35:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/20/2024 08:05:48 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/15/2024 08:05:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:45:43 PM
- Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors • GlobeNewswire Inc. • 02/13/2024 11:00:00 AM
- Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™ • GlobeNewswire Inc. • 12/18/2023 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM